Danaher (NYSE:DHR) Given New $250.00 Price Target at The Goldman Sachs Group

Danaher (NYSE:DHR) had its target price hoisted by The Goldman Sachs Group from $225.00 to $250.00 in a research note issued to investors on Wednesday morning, Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the conglomerate’s stock.

Other equities research analysts have also issued reports about the stock. Robert W. Baird lifted their price target on shares of Danaher from $259.00 to $271.00 and gave the company an outperform rating in a report on Wednesday, April 24th. StockNews.com lowered shares of Danaher from a buy rating to a hold rating in a report on Tuesday, June 25th. Citigroup lifted their price target on shares of Danaher from $280.00 to $290.00 and gave the company a buy rating in a report on Wednesday, April 24th. Bank of America lifted their price target on shares of Danaher from $270.00 to $275.00 and gave the company a neutral rating in a report on Wednesday. Finally, HSBC raised shares of Danaher from a hold rating to a buy rating and lifted their price target for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Danaher has a consensus rating of Moderate Buy and a consensus price target of $276.88.

Danaher Price Performance

DHR stock opened at $273.91 on Wednesday. The company has a quick ratio of 1.51, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher has a 12 month low of $182.09 and a 12 month high of $277.72. The firm has a market cap of $197.82 billion, a P/E ratio of 46.43, a P/E/G ratio of 4.18 and a beta of 0.83. The company’s 50-day moving average price is $255.16 and its two-hundred day moving average price is $249.22.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the firm earned $2.05 EPS. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. On average, analysts anticipate that Danaher will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, July 26th. Stockholders of record on Friday, June 28th were given a $0.27 dividend. The ex-dividend date was Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Transactions at Danaher

In other news, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now owns 116,202 shares in the company, valued at approximately $28,304,483.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Rainer Blair sold 19,085 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $29,578,725. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 84,775 shares of company stock worth $21,802,690. Company insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Cary Street Partners Investment Advisory LLC raised its holdings in Danaher by 20.2% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after buying an additional 1,533 shares during the last quarter. First Citizens Bank & Trust Co. raised its holdings in Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after buying an additional 149 shares during the last quarter. Cercano Management LLC raised its holdings in Danaher by 11.4% during the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after buying an additional 20,715 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Danaher by 48.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after buying an additional 96,395 shares during the last quarter. Finally, Donaldson Capital Management LLC raised its holdings in Danaher by 5.8% during the first quarter. Donaldson Capital Management LLC now owns 1,469 shares of the conglomerate’s stock worth $367,000 after buying an additional 80 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.